Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis

Silvia von Karstedt, Annalisa Conti, Max Nobis, +28

Cancer Cell

Cancer ResearchSignal TransductionSignaling PathwayMedicineReceptor Tyrosine Kinase +8

Central Inhibition of IKKβ/NF-κB Signaling Attenuates High-Fat Diet–Induced Obesity and Glucose Intolerance

Jonas Benzler, Goutham K. Ganjam, Dominik Pretz, +7

Diabetes

Inhibition of IL‐6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer

Freya A. Goumas, Reinhild Holmer, Jan‐Hendrik Egberts, +11

International Journal of Cancer

ImmunologyImmunoeditingCell ProliferationImmunotherapyCancer Biology +16

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B

Mark Wroblewski, R. Bauer, Miguel Cubas Córdova, +11

Nature Communications

Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer

Karen Legler, Ricarda Rosprim, Tosca Karius, +7

British Journal of Cancer

Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma

Angela Zaccagnino, Antonella Managò, Luigi Leanza, +10

Oncotarget

That’s hot: golden spiny mice display torpor even at high ambient temperatures

Kirsten Grimpo, Karen Legler, Gerhard Heldmaier, +1

Journal of Comparative Physiology B

High Ambient TemperaturesPhysiologyRodent EcologyThermodynamicsBiophysics

Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer

Claudia Geismann, Frauke Grohmann, Anita Dreher, +12

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Cancer ImmunosurveillancePancreatic CancerMedicineImmune Cell RecruitmentImmunology +7

Molecular characteristics and tumorigenicity of ascites‐derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer

Yi� Ding, Vera Labitzky, Karen Legler, +5

Molecular Oncology

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells

Karen Legler, Charlotte A. E. Hauser, Jan‐Hendrik Egberts, +13

Cell Death and Disease

Chemoprevention StrategyApoptosisImmunologyCell DeathImmunotherapeutics +19